Incidence of cervical high-grade squamous intraepithelial lesions in HIV-1-infected women with no history of cervical pathology: up to 17 years of follow-up.


Journal

International journal of STD & AIDS
ISSN: 1758-1052
Titre abrégé: Int J STD AIDS
Pays: England
ID NLM: 9007917

Informations de publication

Date de publication:
01 2019
Historique:
pubmed: 2 9 2018
medline: 23 7 2019
entrez: 2 9 2018
Statut: ppublish

Résumé

Currently, Papanicolaou smears are proposed at three-year intervals for cervical screening to all women living with HIV. The aim of this retrospective cohort study was to provide data on the incidence of cervical high-grade squamous intraepithelial lesions (HSIL) in cervical smear confirmed by histology in HIV-1-infected women (two consecutive normal Papanicolaou smears at baseline) after a long-term follow-up. Sixty-seven women (recruited between March 1999 and January 2003) were analyzed. The median period of follow-up was 13.2 years (range: 7.4-17.1 years) with a total of 583 Papanicolaou smears. Twenty-seven percent of these HIV-1-infected women had poorly-controlled HIV. Cumulative incidence of HSIL was 18% (12/67; 95%CI: 11-29%) of which one was an invasive squamous cell carcinoma and two were carcinoma in situ. These women had not been well-engaged with the annual Papanicolaou smear screening program and had poor adherence to antiretroviral therapy. Development of HSIL was associated with high-risk-HPV infection (OR: 14.9; 95%CI: 3.0, 75.1). At last Papanicolaou smear, prevalence of high-risk-HPV infection was 30% (20/66, 95%CI: 21-42%). In conclusion, the incidence of cervical HSIL in HIV-1-infected women with poor antiretroviral therapy adherence or poor immunological status reinforces the need to identify those HIV-1-infected women at risk of developing cervical cancer.

Identifiants

pubmed: 30170532
doi: 10.1177/0956462418792653
doi:

Substances chimiques

Anti-HIV Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

56-63

Auteurs

Sebastián Videla (S)

1 Lluita Contra La SIDA Foundation and AIDS Unit, University Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Catalonia, Spain.
2 Clinical Research Support Unit, Clinical Pharmacology Department, Bellvitge University Hospital/Bellvitge Biomedical Research Institute (IDIBELL)/University of Barcelona, L'Hospitalet del Llobregat, Barcelona.

Antoni Tarrats (A)

3 Department of Gynecology, University Hospital Germans Trias i Pujol, Badalona, Universitat Autònoma de Barcelona, Badalona, Catalonia, Spain.

Arelly Ornelas (A)

1 Lluita Contra La SIDA Foundation and AIDS Unit, University Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Catalonia, Spain.

Roger Badia (R)

4 AIDS Research Institute-IrsiCaixa, University Hospital Germans Trias i Pujol, Badalona, Spain.

Eva Castella (E)

5 Department of Pathology, University Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Catalonia, Spain.

Carme Alcalde (C)

1 Lluita Contra La SIDA Foundation and AIDS Unit, University Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Catalonia, Spain.

Anna Chamorro (A)

1 Lluita Contra La SIDA Foundation and AIDS Unit, University Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Catalonia, Spain.

José A Esté (JA)

4 AIDS Research Institute-IrsiCaixa, University Hospital Germans Trias i Pujol, Badalona, Spain.

Bonaventura Clotet (B)

1 Lluita Contra La SIDA Foundation and AIDS Unit, University Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Catalonia, Spain.
4 AIDS Research Institute-IrsiCaixa, University Hospital Germans Trias i Pujol, Badalona, Spain.

Guillem Sirera (G)

1 Lluita Contra La SIDA Foundation and AIDS Unit, University Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Catalonia, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH